Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs Standard ADT in Hormone Sensitive Prostate Cancer
NCT02278185Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Metabolic Syndrome Incidence (12 months). Started Nov 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02278185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278185.